NEW YORK (GenomeWeb News) – UK firm Epistem today announced its intention to raise £4.2 million ($6.7 million) in net proceeds in preparation of the launch of its molecular diagnostics platform and a tuberculosis assay.

The company will place 793,398 new ordinary shares of its stock at 1.5 pence each with new and existing investors. The shares have been conditionally placed at a price of 545 pence per share, a 4 percent discount to Epistem's closing price on Dec. 6, the company said.

Peel Hunt is underwriting the placement.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

In PLOS this week: grey wolf population genomics, mutations associated with lung adenocarcinoma survival, and more.

An opinion piece at Bloomberg discusses China's stance on genomic research.

Genetic ancestry testing can affect a person's sense of identity, the New York Times Magazine writes.

Nebula Genomics is launching its genome sequencing service for free for people who provide certain information about themselves, the Boston Globe reports.

Nov
29
Sponsored by
Schott

This webinar will discuss how understanding the relative performance characteristics of glass and polymer substrates for in vitro diagnostic applications such as microarrays and microfluidics can help to optimize diagnostic performance.

Dec
04
Sponsored by
Sophia Genetics

This webinar will discuss the use of clinical-grade exome analysis application in complex case investigations.

Dec
11
Sponsored by
PerkinElmer

This webinar describes a study that used two independent next-generation sequencing (NGS) platforms to gain insight into the impact of different types of aneuploidies during preimplantation genetic testing.

Dec
12
Sponsored by
Illumina

This webinar will discuss the use of shotgun metagenomics to identify children at risk of hospital-acquired infection.